As the calendar is about to turn to a new year, not a lot has changed for Accuray (NASDAQ:ARAY) and that's a bad thing. This past year was supposed to be a big one for the company, but it really didn't live up to expectations. Management deserves some credit for improving the cost structure, the go-to-market strategy, and resolving some of its liquidity and dilution issues.
The challenges in front of Accuray remain the same. Can the company's high-quality CyberKnife system drive adoption of stereotactic radiation therapy? Can the company's much-improved image-guided platform drive meaningful share gain in single-vault centers? Simply put, can Accuray emerge as a meaningful player in the radiation therapy landscape alongside Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY)? The current valuation says "no", which aggressive and bullish investors may regard as an ongoing opportunity for the shares.
Follow this link for more:
Accuray Running Low On Chances